Cerebrolysin vs Thymosin Alpha-1
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
CerebrolysinImmune SupportAnti-Aging & Longevity
Thymosin Alpha-1- Summary
- Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Half-Life
- Variable for the complex; individual peptide fractions: minutes to hours
- 2–3 hours
- Admin Route
- IV, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mL
- 0.8–1.6 mg
- Frequency
- Daily for 10–20 days
- Twice weekly
- Key Benefits
- Promotes neurogenesis and synaptic plasticity
- Approved for stroke rehabilitation (accelerates recovery)
- Alzheimer's disease: slows progression and improves cognition
- Traumatic brain injury recovery
- Enhances memory and executive function
- Neuroprotection against oxidative stress and excitotoxicity
- Anti-amyloid and anti-tau effects
- Mood improvement and reduced anxiety
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Side Effects
- Generally well tolerated
- Mild nausea and dizziness (IV infusion)
- Headache at initiation
- Rare: agitation (usually at very high doses)
- +2 more
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Stacks With
- —
- —